Pharmacological therapies for Liposarcoma

References

• Fletcher CDM , Bridge JA , Hogendoorn PCW , et al. editors. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press; 2013.
   Google Scholar
• Ducimetière F , Lurkin A , Ranchère-Vince D , et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294.
   PubMed Web of Science ®Google Scholar
• Henricks WH , Chu YC , Goldblum JR , et al. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol. 1997 Mar;21(3):271–281.
   PubMed Web of Science ®Google Scholar
• Jour G , Gullet A , Liu M , et al. Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Mod Pathol. 2015 Jan;28(1):37–47.
   PubMed Web of Science ®Google Scholar
• Dodd LG. Update on liposarcoma: a review for cytopathologists. Diagn Cytopathol. 2012 Dec;40(12):1122–1131.
   PubMed Web of Science ®Google Scholar
• Singer S , Antonescu CR , Riedel E , et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003 Sep;238(3):358–371. discussion 370-1.
   PubMed Web of Science ®Google Scholar
• Dei Tos AP , Doglioni C , Piccinin S , et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol. 2000 Apr;190(5):531–536.
   PubMed Web of Science ®Google Scholar
• Saponara M , Stacchiotti S , Gronchi A. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. Expert Rev Anticancer Ther. 2016 May;16(5):473–484.
   PubMed Web of Science ®Google Scholar
• Jones RL , Fisher C , Al-Muderis O , et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec;41(18):2853–2860.
   PubMed Web of Science ®Google Scholar
• Crozat A , Aman P , Mandahl N , et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993 Jun 17;363(6430):640–644.
   PubMed Web of Science ®Google Scholar
• Dal Cin P , Sciot R , Panagopoulos I , et al. Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features. J Pathol. 1997 Aug;182(4):437–441.
   PubMed Web of Science ®Google Scholar
• Downes KA , Goldblum JR , Montgomery EA , et al. Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases. Mod Pathol. 2001 Mar;14(3):179–184.
   PubMed Web of Science ®Google Scholar
• Gebhard S , Coindre JM , Michels JJ , et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002 May;26(5):601–616.
   PubMed Web of Science ®Google Scholar
• Ghadimi MP , Liu P , Peng T , et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011 Dec 1;117(23):5359–5369.
   PubMed Web of Science ®Google Scholar
• Steward WP , Verweij J , Somers R , et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1993 Jan;11(1):15–21.
   PubMed Web of Science ®Google Scholar
• Edmonson JH , Ryan LM , Blum RH , et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 Jul;11(7):1269–1275.
   PubMed Web of Science ®Google Scholar
• Antman K , Crowley J , Balcerzak SP , et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276–1285.
   PubMed Web of Science ®Google Scholar
• Santoro A , Tursz T , Mouridsen H , et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537–1545.
   PubMed Web of Science ®Google Scholar
• Le Cesne A , Judson I , Crowther D , et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 Jul;18(14):2676–2684.
   PubMed Web of Science ®Google Scholar
• Van Oosterom AT , Mouridsen HT , Nielsen OS , et al. EORTC Soft Tissue and Bone Sarcoma Group. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002 Dec;38(18):2397–2406.
   PubMed Web of Science ®Google Scholar
• Worden FP , Taylor JM , Biermann JS , et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol. 2005 Jan 1;23(1):105–112.
   PubMed Web of Science ®Google Scholar
• Fayette J , Penel N , Chevreau C , et al. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs. 2009 Oct;27(5):482–489.
   PubMed Web of Science ®Google Scholar
• Maurel J , López-Pousa A , De Las Peñas R , et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol. 2009 Apr 10;27(11):1893–1898.
   PubMed Web of Science ®Google Scholar
• Verma S , Younus J , Stys-Norman D , et al. Members of the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev. 2008 Jun;34(4):339–347.
   PubMed Web of Science ®Google Scholar
• Judson I , Verweij J , Gelderblom H , et al. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415–423.
   PubMed Web of Science ®Google Scholar
• Leahy M , Garcia Del Muro X , Reichardt P , et al. SABINE Investigators. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Ann Oncol. 2012 Oct;23(10):2763–2770.
   PubMed Web of Science ®Google Scholar
• Reichardt P , Leahy M , Garcia Del Muro X , et al. Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: the sarcoma treatment and burden of illness in North America and Europe (SABINE) Study. Sarcoma. 2012;2012:1–11.
   Google Scholar
• Sanfilippo R , Bertulli R , Marrari A , et al. High-dose continuous infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res. 2014 Nov 22;4(1):16.
   PubMedGoogle Scholar
• Maki RG , Wathen JK , Patel SR , et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007 Jul 1;25(19):2755–2763.
   PubMed Web of Science ®Google Scholar
• García-Del-Muro X , López-Pousa A , Maurel J , et al. Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011 Jun 20;29(18):2528–2533.
   PubMed Web of Science ®Google Scholar
• Italiano A , Toulmonde M , Cioffi A , et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol. 2012 Jun;23(6):1601–1607.
   PubMed Web of Science ®Google Scholar
• Italiano A , Garbay D , Cioffi A , et al. Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Ann Oncol. 2012 Aug;23(8):2205–2206.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M , Van Oosterom AT , Oosterhuis JW , et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999 Jan;17(1):150–157.
   PubMed Web of Science ®Google Scholar
• Larsen AK , Galmarini CM , D’Incalci M . Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol. 2016 Apr;77(4):663–671.
   PubMed Web of Science ®Google Scholar
• Germano G , Frapolli R , Belgiovine C , et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013 Feb 11;23(2):249–262.
   PubMed Web of Science ®Google Scholar
• Allavena P , Germano G , Belgiovine C , et al. Trabectedin: a drug from the sea that strikes tumor-associated macrophages. Oncoimmunology. 2013 Jun 1;2(6):e24614.
   PubMed Web of Science ®Google Scholar
• Puchalski TA , Ryan DP , Garcia-Carbonero R , et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002 Oct;50(4):309–319.
   PubMed Web of Science ®Google Scholar
• Ryan DP , Supko JG , Eder JP , et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001 Feb;7(2):231–242.
   PubMed Web of Science ®Google Scholar
• Twelves C , Hoekman K , Bowman A , et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer. 2003 Sep;39(13):1842–1851.
   PubMed Web of Science ®Google Scholar
• Villalona-Calero MA , Eckhardt SG , Weiss G , et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002 Jan;8(1):75–85.
   PubMed Web of Science ®Google Scholar
• Taamma A , Misset JL , Riofrio M , et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001 Mar 1;19(5):1256–1265.
   PubMed Web of Science ®Google Scholar
• Yovine A , Riofrio M , Blay JY , et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004 Mar 1;22(5):890–899.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R , Supko JG , Manola J , et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004 Apr 15;22(8):1480–1490.
   PubMed Web of Science ®Google Scholar
• Le Cesne A , Blay JY , Judson I , et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005 Jan 20;23(3):576–584.
   PubMed Web of Science ®Google Scholar
• Demetri GD , Chawla SP , Von Mehren M , et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188–4196.
   PubMed Web of Science ®Google Scholar
• Demetri GD , Von Mehren M , Jones RL , et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10;34(8):786–793.
   PubMed Web of Science ®Google Scholar
• Patel S, Von Mehren M, Reed D, et al. Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS), M. Eur J Cancer. 2015 September;51(3):S689.
   Google Scholar
• Stacchiotti S , Collini P , Messina A , et al. High-grade soft-tissue sarcomas: tumor response assessment–pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology. 2009 May;251(2):447–456.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S , Verderio P , Messina A , et al. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer. 2012 Dec 1;118(23):5857–5866.
   PubMed Web of Science ®Google Scholar
• Hollebecque A , Adenis A , Taieb S , et al. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Invest New Drugs. 2010 Aug;28(4):529–530.
   PubMed Web of Science ®Google Scholar
• Taieb S , Saada-Bouzid E , Tresch E , et al. French Sarcoma Group. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. Eur J Cancer. 2015 Jan;51(2):202–209.
   PubMed Web of Science ®Google Scholar
• Germano G , Frapolli R , Simone M , et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010 Mar 15;70(6):2235–2244.
   PubMed Web of Science ®Google Scholar
• Charytonowicz E , Terry M , Coakley K , et al. PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest. 2012 Mar;122(3):886–898.
   PubMed Web of Science ®Google Scholar
• Dossi R , Frapolli R , Di Giandomenico S , et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer. 2015 Feb 1;136(3):721–729.
   PubMed Web of Science ®Google Scholar
• Forni C , Minuzzo M , Virdis E , et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009 Feb;8(2):449–457.
   PubMed Web of Science ®Google Scholar
• Di Giandomenico S , Frapolli R , Bello E , et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene. 2014 Oct 30;33(44):5201–5210.
   PubMed Web of Science ®Google Scholar
• Grosso F , Jones RL , Demetri GD , et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8(7):595–602.
   PubMed Web of Science ®Google Scholar
• Grosso F , Sanfilippo R , Virdis E , et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009 Aug;20(8):1439–1444.
   PubMed Web of Science ®Google Scholar
• Blay JY , Italiano A , Ray-Coquard I , et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer. 2013 Feb 6;13:64.
   PubMed Web of Science ®Google Scholar
• Le Cesne A , Ray-Coquard I , Duffaud F , et al. French Sarcoma Group. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer. 2015 Apr;51(6):742–750.
   PubMed Web of Science ®Google Scholar
• Le Cesne A , Blay JY , Domont J , et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015;16(3):312–319.
   PubMed Web of Science ®Google Scholar
• Le Cesne A , Judson I , Maki R , et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer. 2013 Oct 1;109(7):1717–1724.
   PubMed Web of Science ®Google Scholar
• Schöffski P , Ray-Coquard IL , Cioffi A , et al. European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045–1052.
   PubMed Web of Science ®Google Scholar
• Schöffski P , Chawla S , Maki RG , et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629–1637.
   PubMed Web of Science ®Google Scholar
• Towle MJ , Salvato KA , Budrow J , et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001 Feb 1;61(3):1013–1021.
   PubMed Web of Science ®Google Scholar
• Jordan MA , Kamath K , Manna T , et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005 Jul;4(7):1086–1095.
   PubMed Web of Science ®Google Scholar
• Okouneva T , Azarenko O , Wilson L , et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008 Jul;7(7):2003–2011.
   PubMed Web of Science ®Google Scholar
• Wozniak KM , Nomoto K , Lapidus RG , et al. Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res. 2011 Jun 1;71(11):3952–3962.
   PubMed Web of Science ®Google Scholar
• Cortes J , O’Shaughnessy J , Loesch D , et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet. 2011 Mar 12;377(9769):914–923.
   PubMed Web of Science ®Google Scholar
• Kaufman PA , Awada A , Twelves C , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20;33(6):594–601.
   PubMed Web of Science ®Google Scholar
• Chawla SP , Schöffski P , Grignani G , et al. Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS). J Clin Oncol. 2016;34. (suppl; abstr 11037).
   PubMed Web of Science ®Google Scholar
• Paulsson J , Ehnman M , Östman A . PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol. 2014;10(9):1695–1708.
   PubMed Web of Science ®Google Scholar
• Tap WD , Jones RL , Van Tine BA , et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488–497.
   PubMed Web of Science ®Google Scholar
• A study of doxorubicin plus olaratumab (LY3012207) in participants with advanced or metastatic soft tissue sarcoma (ANNOUNCE). Available from: https://clinicaltrials.gov/ct2/show/NCT02451943
   Google Scholar
• Potti A , Ganti AK , Tendulkar K , et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol. 2004 Jan;130(1):52–56.
   PubMed Web of Science ®Google Scholar
• Potti A , Ganti AK , Foster H , et al. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res. 2004 Jan–Feb;24(1):333–337.
   PubMed Web of Science ®Google Scholar
• Pakos EE , Goussia AC , Tsekeris PG , et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res. 2005 Sep–Oct;25(5):3591–3596.
   PubMed Web of Science ®Google Scholar
• Chao C , Al-Saleem T , Brooks JJ , et al. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001 Apr;8(3):260–267.
   PubMed Web of Science ®Google Scholar
• Yudoh K , Kanamori M , Ohmori K , et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 2001 Jun 15;84(12):1610–1615.
   PubMed Web of Science ®Google Scholar
• DuBois S , Demetri G . Markers of angiogenesis and clinical features in patients with sarcoma [ Review]. Cancer. 2007 Mar 1;109(5):813–819.
   PubMed Web of Science ®Google Scholar
• Sleijfer S , Van Der Graaf WT , Blay JY . Angiogenesis inhibition in non-GIST soft tissue sarcomas. Oncologist. 2008 Nov;13(11):1193–1200.
   PubMed Web of Science ®Google Scholar
• Mahmood ST , Agresta S , Vigil CE , et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011 Oct 15;129(8):1963–1969.
   PubMed Web of Science ®Google Scholar
• Von Mehren M , Rankin C , Goldblum JR , et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb 1;118(3):770–776.
   PubMed Web of Science ®Google Scholar
• Brodowicz T , Liegl-Atzwager B , Tresch E , et al. Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. BMC Cancer. 2015 Mar 14;15:127.
   PubMed Web of Science ®Google Scholar
• Sleijfer S , Ray-Coquard I , Papai Z , et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009 Jul 1;27(19):3126–3132.
   PubMed Web of Science ®Google Scholar
• Van Der Graaf WT , Blay JY , Chawla SP , et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879–1886.
   PubMed Web of Science ®Google Scholar
• Study of pazopanib in the treatment of surgically unresectable or metastatic liposarcoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01506596
   Google Scholar
• Activity and tolerability of pazopanib in advanced and/or metastatic liposarcoma. A Phase II Clinical Trial. Available from: https://clinicaltrials.gov/ct2/show/NCT01692496
   Google Scholar
• Müller CR , Paulsen EB , Noordhuis P , et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer. 2007 Jul 1;121(1):199–205.
   PubMed Web of Science ®Google Scholar
• Singer S , Socci ND , Ambrosini G , et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007 Jul 15;67(14):6626–6636.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I , Blay JY , Italiano A , et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012 Nov;13(11):1133–1140.
   PubMed Web of Science ®Google Scholar
• A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery. Available from: https://clinicaltrials.gov/ct2/show/NCT01143740
   Google Scholar
• A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01605526
   Google Scholar
• Ambrosini G , Sambol EB , Carvajal D , et al. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene. 2007 May 24;26(24):3473–3481.
   PubMed Web of Science ®Google Scholar
• Luke JJ , D’Adamo DR , Dickson MA , et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res. 2012 May 1;18(9):2638–2647.
   PubMed Web of Science ®Google Scholar
• Schwartz GK , LoRusso PM , Dickson MA , et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011 Jun 7;104(12):1862–1868.
   PubMed Web of Science ®Google Scholar
• Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02343172
   Google Scholar
• Study of Abemaciclib in Dedifferentiated Liposarcoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02846987
   Google Scholar
• Dickson MA , Tap WD , Keohan ML , et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013 Jun 1;31(16):2024–2028.
   PubMed Web of Science ®Google Scholar
• Dickson MA , Schwartz GK , Keohan ML , et al. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 Clinical Trial. JAMA Oncol. 2016 Jul 1;2(7):937–940.
   PubMed Web of Science ®Google Scholar
• Tontonoz P , Singer S , Forman BM , et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237–241.
   PubMed Web of Science ®Google Scholar
• Demetri GD , Fletcher CD , Mueller E , et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951–3956.
   PubMed Web of Science ®Google Scholar
• Debrock G , Vanhentenrijk V , Sciot R , et al. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer. 2003 Oct 20;89(8):1409–1412.
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ , Marshall JL , Wagner AJ , et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012 Nov 1;118(21):5403–5413.
   PubMed Web of Science ®Google Scholar
• Rosiglitazone in treating patients with liposarcoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00004180
   Google Scholar
• Hodi FS , O’Day SJ , McDermott DF , et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Jungbluth AA , Antonescu CR , Busam KJ , et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer. 2001 Oct 15;94(2):252–256.
   PubMed Web of Science ®Google Scholar
• Robbins PF , Morgan RA , Feldman SA , et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 1;29(7):917–924.
   PubMed Web of Science ®Google Scholar
• Lai JP , Robbins PF , Raffeld M , et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol. 2012 Jun;25(6):854–858.
   PubMed Web of Science ®Google Scholar
• Bertucci F , Finetti P , Mamessier E , et al. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology. 2015 Feb 3;4(5):e1002729.
   PubMed Web of Science ®Google Scholar
• Seifert AM , Zeng S , Zhang JQ , et al. PD-1/PD-L1 blockade enhances T cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2016 Jul 28. Published Online First July 28, 2016. DOI:10.1158/1078-0432.CCR-16-1163
   Web of Science ®Google Scholar
• Pollack SM , Jungbluth AA , Hoch BL , et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012 Sep 15;118(18):4564–4570.
   PubMed Web of Science ®Google Scholar
• Shurell E , Vergara-Lluri ME , Li Y , et al. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. Oncotarget. 2016 Sep 17. Published online 17 Sep 2016. DOI:10.18632/oncotarget.12096
   Web of Science ®Google Scholar
• Trial of CMB305 and atezolizumab in patients with sarcoma (IMDZ-C232). Available from: https://clinicaltrials.gov/ct2/show/NCT02609984
   Google Scholar
• Wolchok JD , Hoos A , O’Day S , et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412–7420.
   PubMed Web of Science ®Google Scholar